219 related articles for article (PubMed ID: 36577483)
1. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
2. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
Flynn R; Allen JL; Luznik L; MacDonald KP; Paz K; Alexander KA; Vulic A; Du J; Panoskaltsis-Mortari A; Taylor PA; Poe JC; Serody JS; Murphy WJ; Hill GR; Maillard I; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Chao NJ; Clynes RA; Sarantopoulos S; Blazar BR
Blood; 2015 Jun; 125(26):4085-94. PubMed ID: 25852057
[TBL] [Abstract][Full Text] [Related]
3. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
5. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
7. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
8. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
9. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
13. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Vergis N; Phillips R; Cornelius V; Katsarou A; Youngstein T; Cook L; Willicombe M; Pilay C; Shturova T; Almonte M; Charania A; Turner R; Kon OM; Cooke G; Thursz M; Cherlin S; Wason J; Milojkovic D; Innes AJ; Cooper N
Trials; 2021 Apr; 22(1):270. PubMed ID: 33845867
[TBL] [Abstract][Full Text] [Related]
14. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
16. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
18. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
19. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Scott DL
Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]